MARKET

ARVN

ARVN

Arvinas
NASDAQ

Real-time Quotes | Nasdaq Last Sale

51.52
-0.09
-0.17%
Opening 10:56 01/29 EST
OPEN
51.71
PREV CLOSE
51.61
HIGH
52.54
LOW
51.12
VOLUME
18.51K
TURNOVER
--
52 WEEK HIGH
52.93
52 WEEK LOW
14.07
MARKET CAP
1.61B
P/E (TTM)
-25.0012
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARVN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ARVN News

  • Will Arvinas Continue to Surge Higher?
  • Zacks.4h ago
  • Wedbush Maintains Outperform on Arvinas, Raises Price Target to $60
  • Benzinga.5d ago
  • What Company Will Eli Lilly Buy Next?
  • MotleyFool.com.6d ago
  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.01/17 13:07

More

Industry

Pharmaceuticals
+0.50%
Pharmaceuticals & Medical Research
+0.40%

Hot Stocks

Name
Price
%Change

About ARVN

Arvinas, Inc., formerly Arvinas Holding Co LLC, is a development staged biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The Company uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The Company is using its PROTAC platform to build an pipeline of protein degradation product candidates to target diseases in a wide range of organ systems and tissues. It is also focused on advancing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. It seeks to initiate a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), and a Phase 1 clinical trial for ARV-471 in women with metastatic ER positive, HER2 negative breast cancer, or ER+ breast cancer.
More

Webull offers Arvinas Inc (ARVN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.